Literature DB >> 2525440

The increase of non-MHC-restricted cytotoxic cells (gamma/delta-TCR-bearing T cells or NK cells) and the abnormal differentiation of B cells in Wiskott-Aldrich syndrome.

T Morio1, K Takase, H Okawa, M Oguchi, M Kanbara, F Hiruma, K Yoshino, T Kaneko, S Asamura, T Inoue.   

Abstract

The objective of this study was to analyze the configuration of the lymphocytes in Wiskott-Aldrich syndrome (WAS) by studying the surface antigens from nine cases using dual-color immunofluorescence analysis. All the patients showed the increase of non-MHC-restricted cytotoxic cells, namely CD3+ WT31- delta TCS1+ (gamma/delta-T cell receptor (TCR)-bearing cells) and/or CD16+ natural killer cells. The gamma/delta-TCR+ cells of WAS, however, were unique since they did not express CD5, which is present on ordinary gamma/delta-TCR+ cells. A reduced number of CD4+ cells and an increased percentage of CD11b+ Leu7+ cells within a CD8+ subset were observed in all cases. With regard to B cell subpopulations, most cases showed reduced Fc epsilon R2-bearing B cells, despite an elevated serum IgE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525440     DOI: 10.1016/0090-1229(89)90179-7

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  11 in total

1.  Suppression of in vitro immunoglobulin synthesis by CD16(Leu11a)+ CD56 (NKH1,Leu19)+non-T lineage NK cells; lack of suppression of cells from immunodeficient patients.

Authors:  T Morio; S Nonoyama; J Yata
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  Impaired cell adhesion, apoptosis, and signaling in WASP gene-disrupted Nalm-6 pre-B cells and recovery of cell adhesion using a transducible form of WASp.

Authors:  Rikiya Sato; Susumu Iiizumi; Eun-Sung Kim; Fumiko Honda; Sang-Kyou Lee; Noritaka Adachi; Hideki Koyama; Shuki Mizutani; Tomohiro Morio
Journal:  Int J Hematol       Date:  2012-02-05       Impact factor: 2.490

Review 3.  Wiskott-Aldrich syndrome: a multidisciplinary disease.

Authors:  G R Standen
Journal:  J Clin Pathol       Date:  1991-12       Impact factor: 3.411

4.  Phenotypic perturbation of B cells in the Wiskott-Aldrich syndrome.

Authors:  J Y Park; A Shcherbina; F S Rosen; A P Prodeus; E Remold-O'Donnell
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

5.  Evidence for defective transmembrane signaling in B cells from patients with Wiskott-Aldrich syndrome.

Authors:  H U Simon; G B Mills; S Hashimoto; K A Siminovitch
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

6.  Association of increased numbers of peripheral blood double-negative T-lymphocytes with elevated serum IgG levels in severely handicapped children.

Authors:  Y Kawano; T Noma; I Yoshizawa; K Maruki; J Yata
Journal:  Eur J Pediatr       Date:  1994-12       Impact factor: 3.183

7.  Differential staining of human alpha beta and gamma delta T cells by the fluorescein conjugate of an anti-CD3 monoclonal antibody.

Authors:  J E Mullersman; G White; K S Tung
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

8.  Early deficit of lymphocytes in Wiskott-Aldrich syndrome: possible role of WASP in human lymphocyte maturation.

Authors:  J Y Park; M Kob; A P Prodeus; F S Rosen; A Shcherbina; E Remold-O'Donnell
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

9.  Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes.

Authors:  J Zhang; A Shehabeldin; L A da Cruz; J Butler; A K Somani; M McGavin; I Kozieradzki; A O dos Santos; A Nagy; S Grinstein; J M Penninger; K A Siminovitch
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

Review 10.  Signal Integration during T Lymphocyte Activation and Function: Lessons from the Wiskott-Aldrich Syndrome.

Authors:  Vinicius Cotta-de-Almeida; Loïc Dupré; Delphine Guipouy; Zilton Vasconcelos
Journal:  Front Immunol       Date:  2015-02-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.